RxDoctor Payments Data

Amanda Tanhchaleun

Nurse Practitioner · Honolulu, HINPI 1578042461

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.3% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 42.2% of the total. Reporting peaked in 2023 at $1,407 and has fallen 82.6% since, to $245 in 2025. Among nurse practitioner clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,198in general payments, 2019–2025

Across 98 payments — averaging $42.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Boehringer Ingelheim$553
  • Abbott$424
  • Mannkind Corporation$305
  • Dexcom, Inc.$294
  • AstraZeneca$250
  • plus $603 from 7 others

What the payments were for

  • Food & beverage$3,83491%
  • Education$3649%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,198 in reported general payments places this provider in the 90th percentile of 215 nurse practitioner providers in Hawaii.

See all nurse practitioner providers in Hawaii

Medicare billing

Part B allowed, 2024
$25,179
Medicare patients
84
Services billed
308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide25$24,154
JardianceEmpagliflozin14$8,012
JanuviaSitagliptin Phosphate12$6,682
Nano 2nd Gen Pen NeedlePen Needle, Diabetic34$2,316
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,649
Single Use SwabAlcohol Antiseptic Pads29$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$128$24,15425 claims
Boehringer IngelheimJardiance$553$8,01214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 215 nurse practitioner providers in Hawaii.

Other nurse practitioner in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →